Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. It markets several products for surgical and chronic wound care applications and has multiple products in its pipeline. Its surgical products, CellerateRX Surgical, TEXAGEN, BiFORM, ACTIGEN, ALLOCYTE, ALLOCYTE Plus Advanced Viable Bone Matrix (ALLOCYTE Plus), BIASURGE, FORTIFY TRG Tissue Repair Graft (FORTIFY TRG), and FORTIFY FLOWABLE Extracellular Matrix (FORTIFY FLOWABLE) are used in a range of surgical specialties to help promote patient healing and reduce the risk of complications. CellerateRX Surgical products, TEXAGEN products, FORTIFY TRG and FORTIFY FLOWABLE are used in specialties, including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, and others.
BörsenkürzelSMTI
Name des UnternehmensSanara Medtech Inc
IPO-datumApr 07, 1994
CEOMr. Suresh V. (Sam) Muppalla
Anzahl der mitarbeiter141
WertpapierartOrdinary Share
GeschäftsjahresendeApr 07
Addresse1200 Summit Avenue
StadtFORT WORTH
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl76102
Telefon18175292300
Websitehttps://sanaramedtech.com/
BörsenkürzelSMTI
IPO-datumApr 07, 1994
CEOMr. Suresh V. (Sam) Muppalla
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten